School of Medicine, University of California, Riverside, USA.
Research to End Healthcare Disparities Corp, I-Lead Institute, Los Angeles, USA.
Drug Alcohol Rev. 2022 Nov;41(7):1653-1663. doi: 10.1111/dar.13522. Epub 2022 Aug 11.
Before COVID-19, Native Hawaiians/Pacific Islanders (NH/PI) endured a heavy burden of alcohol, tobacco and other drug (ATOD) use in prior US data. Responding to reports that many NH/PI communities experienced severe COVID-19 disparities that could exacerbate their ATOD burden, we partnered with NH/PI communities to assess the substance use patterns and treatment needs of diverse NH/PIs during COVID-19.
Collaborating with NH/PI community organisations across five states with large NH/PI populations, we conducted a large-scale investigation of NH/PI ATOD use, mental health and treatment need during COVID-19. Between April and November 2021, NH/PI-heritage research staff from our community partners collected data involving 306 NH/PI adults using several community-based recruitment methods (e-mail, telephone, in-person) and two survey approaches: online and paper-and-pencil. Multivariate regressions were conducted to examine potential predictors of NH/PI alcohol use disorder and need for behavioural health treatment.
During COVID-19, 47% and 22% of NH/PI adults reported current alcohol and cigarette use, while 35% reported lifetime illicit substance use (e.g., cannabis, opioid). Depression and anxiety were high, and alcohol use disorder, major depression and generalised anxiety disorder prevalence were 27%, 27% and 19%, respectively. One-third of participants reported past-year treatment need with lifetime illicit substance use, COVID-19 distress and major depression respectively associating with 3.0, 1.2, and 5.3 times greater adjusted odds for needing treatment.
NH/PI adults reported heavy ATOD use, depression, anxiety and treatment need during COVID-19. Targeted research and treatment services may be warranted to mitigate COVID-19's negative behavioural health impact on NH/PI communities.
在 COVID-19 之前,美国数据显示,夏威夷原住民/太平洋岛民(NH/PI)长期存在酒精、烟草和其他药物(ATOD)使用问题。针对许多 NH/PI 社区经历严重的 COVID-19 差异的报告,这些差异可能会加重他们的 ATOD 负担,我们与 NH/PI 社区合作,在 COVID-19 期间评估不同 NH/PI 人群的物质使用模式和治疗需求。
我们与五个拥有大量 NH/PI 人口的州的 NH/PI 社区组织合作,对 NH/PI 在 COVID-19 期间的 ATOD 使用、心理健康和治疗需求进行了大规模调查。在 2021 年 4 月至 11 月期间,我们的社区合作伙伴中的 NH/PI 裔研究人员使用多种社区招募方法(电子邮件、电话、面对面)和两种调查方法(在线和纸笔)收集了涉及 306 名 NH/PI 成年人的数据。多元回归分析用于研究 NH/PI 酒精使用障碍和行为健康治疗需求的潜在预测因素。
在 COVID-19 期间,47%和 22%的 NH/PI 成年人报告当前饮酒和吸烟,而 35%报告有终生滥用药物史(例如大麻、阿片类药物)。抑郁和焦虑程度较高,酒精使用障碍、重度抑郁症和广泛性焦虑症的患病率分别为 27%、27%和 19%。三分之一的参与者报告过去一年有治疗需求,与终生滥用药物史、COVID-19 困扰和重度抑郁症分别相关的调整后比值比为 3.0、1.2 和 5.3 倍。
NH/PI 成年人在 COVID-19 期间报告了大量的 ATOD 使用、抑郁、焦虑和治疗需求。可能需要有针对性的研究和治疗服务,以减轻 COVID-19 对 NH/PI 社区的负面行为健康影响。